Journal
TRENDS IN IMMUNOLOGY
Volume 22, Issue 7, Pages 386-393Publisher
ELSEVIER SCI LTD
DOI: 10.1016/S1471-4906(01)01943-3
Keywords
-
Categories
Funding
- NCI NIH HHS [5P30 CA16056-25, CA75235, CA33462, CA54491, CA79879] Funding Source: Medline
Ask authors/readers for more resources
The ability to engraft human tumors and human immunocompetent cells successfully in severe combined immunodeficient (SCID) mice has spawned the development and use of human-mouse chimeric models to evaluate anticancer therapies. The lack of standardization and many other potential pitfalls have contributed to the current controversy surrounding the reliability of these different models. Five frequently used SCID mouse models and their specific applications are summarized with the specific aim of providing an objective discussion of the strengths and limitations of each model, together with suggestions for overcoming some of the variabilities and for improving the design and use of future models.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available